Non Invasive Brain Stimulation for PTSD
Non-invasive Brain Stimulation for Post-Traumatic Stress Disorder
2 other identifiers
interventional
18
1 country
1
Brief Summary
This study is designed to identify changes in the brain that underlie symptoms of combat-related PTSD using brain imaging (fMRI). Then, the investigators will administer mild electrical stimulation to the side of the head (using a method called tDCS) in an attempt to reduce the symptoms of PTSD.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for early_phase_1
Started May 2015
Typical duration for early_phase_1
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
February 17, 2015
CompletedStudy Start
First participant enrolled
May 1, 2015
CompletedFirst Posted
Study publicly available on registry
May 13, 2015
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 1, 2017
CompletedStudy Completion
Last participant's last visit for all outcomes
August 1, 2017
CompletedAugust 31, 2018
August 1, 2018
2.3 years
February 17, 2015
August 28, 2018
Conditions
Outcome Measures
Primary Outcomes (1)
Functional Connectivity changes as assessed by fMRI images
Investigators will use the fMRI images taken from before and after tDCS to determine if the treatment intervention contributed to any changes within the neural networks associated with the symptoms of PTSD.
Pre and post tDCS; typically within 4 weeks
Secondary Outcomes (8)
Symptomatic changes as assessed by structured questionnaires (PCL-C)
Pre and post tDCS; typically within 4 weeks
Symptomatic changes as assessed by structured questionnaires (CAPS)
Pre and post tDCS; typically within 4 weeks
Symptomatic changes as assessed by structured questionnaires (Hamilton Depression Rating Scale)
Pre and post tDCS; typically within 4 weeks
Symptomatic changes as assessed by structured questionnaires (State-trait anxiety inventory)
Pre and post tDCS; typically within 4 weeks
Cognitive changes as assessed by Neuropsychological testing
Pre and post tDCS; typically within 4 weeks
- +3 more secondary outcomes
Study Arms (3)
active tDCS
EXPERIMENTALInvestigators will use cathodal tDCS to inhibit the brain regions that may be associated with symptoms of PTSD (temporal cortex). Active tDCS will be provided at 2 miliamps (mA) for 20 minutes (with gradual increase and withdraw of stimulation during the first and last minute).
sham tDCS
SHAM COMPARATORParticipants randomized to the sham condition will receive stimulation during the first and final minutes of the 20 minute period (with gradual increase and removal of current during that time).
Combat Controls
NO INTERVENTIONParticipants without PTSD will undergo neuropsychological testing and a single fMRI scan.
Interventions
Participants will be randomized into active or sham stimulation in the first tDCS session. Participants will then have the option to complete 9 additional session of tDCS which will be active tDCS or a combination of active and sham tDCS in a non-randomized manner over two consecutive weeks. Each session will last 1 - 2 hours.
Participants will be randomized into active or sham stimulation in the first tDCS session. Participants will then have the option to complete 9 additional session of tDCS which will be active tDCS or a combination of active and sham tDCS in a non-randomized manner over two consecutive weeks. Each session will last 1 - 2 hours.
Eligibility Criteria
You may qualify if:
- Male
- Combat Veteran - both Veterans with and without PTSD will be included at different points in this study
- Right-handed
- Between the ages 18-88
- Stable on medications for a minimum of 2 weeks
You may not qualify if:
- a history of neurological disease (e.g., dementia, epilepsy, stroke, moderate - severe traumatic brain injury)
- "severe" Axis I diagnoses (e.g., bipolar disorder, schizophrenia)
- presence of Axis II disorders
- current alcohol or drug abuse/dependence (in the past 8 weeks)
- participants will also be excluded if they are not MRI compatible (assessed using the guidelines of the American College of Radiology)
- Imminent risk of harm to self or others
- history of HIV or sickle cell anemia, as these can cause neuropsychological issues .
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- University of Michiganlead
- National Institute of Mental Health (NIMH)collaborator
Study Sites (1)
University of Michigan Neuropsychology Section
Ann Arbor, Michigan, 48105, United States
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Benjamin Hampstead, PhD
University of Michigan
Study Design
- Study Type
- interventional
- Phase
- early phase 1
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Who Masked
- PARTICIPANT, INVESTIGATOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Investigator
Study Record Dates
First Submitted
February 17, 2015
First Posted
May 13, 2015
Study Start
May 1, 2015
Primary Completion
August 1, 2017
Study Completion
August 1, 2017
Last Updated
August 31, 2018
Record last verified: 2018-08